Duration: 60 minutes
Precision medicine promises tailored treatment for patients and significantly reduced drug failure rates for biopharmaceutical companies. In order to deliver targeted therapeutics, drug developers must design clinical trials that utilize a validated companion diagnostic assay as part of the enrollment criteria, an increasingly difficult prospect as the field moves beyond assays that simply determine the presence of the therapeutic target molecule. Myriad Genetics is uniquely positioned to provide support to pharmaceutical and biotechnology companies via high-complexity diagnostic platforms for DNA, RNA, and protein measurements, vertically-integrated biomarker discovery, clinical validation, and diagnostic commercialization capabilities, all of which are backed by a regulatory infrastructure that achieved the industry’s first FDA approval for a complex companion diagnostic.
Watch this webinar to learn more about how the largest molecular diagnostic clinical laboratory in the world can help identify molecular characteristics linked to complex disease states and drug response phenotypes to improve drug development and help deliver the promise of precision medicine.
Patrick Burke, executive vice president of emerging products, joined the Myriad Genetics, Inc. in 2001. In his current role, he oversees New Product Planning, Business Development and Project Management. Previously, Dr. Burke served as Vice President of Strategic Collaborations and held positions of increasing responsibility within the Business and Corporate Development group at Myriad. Between 2009 and 2011, he served as Vice President of Corporate and Business Development at Myrexis, Inc., a subsidiary of the company. Dr. Burke is an active member of Licensing Executive Society and the Association of University Technology Managers. He earned his Ph.D. in Cell Biology from the University of Utah School of Medicine and his B.A. in Molecular Biology from the University of California, San Diego.
- Clinical and scientific leaders involved in personalized medicine strategies and implementation for drug development programs.
- Individuals and teams tasked with incorporating hereditary and somatic gene mutations, gene expression, and blood-based protein biomarkers in CDx programs, especially in oncology and inflammatory and autoimmune disorders.
- 13 Sep 2016
- Companion Diagnostics, Webinars